PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce
- Conference Call and Webcast Today, August 4, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 4, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022 . The company is hosting a conference call today,
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022 .
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 34
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 5, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce
Fibrosis regression observed in 58% (7 of 12) of patients receiving 200 mg fazirsiran Median reduction of 83% of Z-AAT accumulation in the liver Reduction of 69% in histologic globule burden Substantial and sustained improvements in clinically relevant biomarkers of liver health Osaka, JAPAN,
PASADENA, Calif. --(BUSINESS WIRE)--Jun. 7, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conference – June 8-10, 2022 Type: Fireside chat presentation Presenter: Vincent Anzalone ,
PASADENA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its
- Conference Call and Webcast Today, May 10, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 10, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022 . The company is hosting a conference call today,